Possible Biomarkers and Therapeutic Targets for the Management of Cervical Cancer

Author(s): Sombeer Sharma, Aakash Deep*, Avtar C. Rana, Monu Yadav, Arun K. Sharma.

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Introduction: Cervical cancer is the most prevalent cancer in the world due to unusual extension of cervical cell. Cervical cancer occurs due to exposure of HPV (Human papillomavirus). According to WHO, it is the 4th most ordinary cancer in women. In 2018, approx 6.6% of population was affected around the world and 570,000 new cases were reported. In low and middle-income countries, 90% of cervical cancer deaths occur.

Methods: Despite various factors that cause cervical cancer are included exposure to HPV, dysregulation of CASPASE enzyme, elevated expression of IAPs (Inhibitor apoptotic protein), E6 and E7 gene of HPV, inhibition of p53, BAK, p16 upregulation, CDK-inactivation causing cervical cancer, role of VEGF, role of estrogen and its receptor in cervical cancer.

Results: Cervical cancer can be screened by Pep test. There are various therapies that can be used to treat cervical cancer. As these therapies have various side effects, so the world is moving to herbal formulations to treat cervical cancer.

Conclusion: In this study, we will discuss cervical cancer, its cause, symptoms, pathophysiology and treatments. Early screening and detection can help in reducing the overall burden of cervical cancer in the near future.

Keywords: Cervical cancer, symptoms, pathophysiology, possible treatments, cervical cells, contraceptive pills.

[1]
Lei J, Ploner A, Lagheden C, et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. PLoS Med 2018; 15(10) e1002666
[2]
Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55(4): 244-65.
[3]
Anderson L, Henderson C, Adachi Y. Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage. Mol Cell Biol 2001; 21(5): 1719-29.
[4]
Ren G, Zhao YP, Yang L, Fu CX. Anti-proliferative effect of clitocine from the mushroom Leucopaxillus giganteus on human cervical cancer HeLa cells by inducing apoptosis. Cancer Lett 2008; 262(2): 190-200.
[5]
Park I, Park KK, Park JHY and, Chung WY. Isoliquiritigenin induces G2 and M phase arrest by inducing DNA damage and by inhibiting the metaphase/anaphase transition. Cancer Lett 2009; 277(2): 174-81.
[6]
Simon AE, Waller J, Robb KA, Wardle J. Patient delay in presentation of possible cancer symptoms: The contribution of knowledge and attitudes in a UK population sample. Cancer Epidemiol Biomarkers Prev 2010; 19(9): 2272-7.
[7]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[8]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[9]
Bruni L, Barrionuevo-Rosas L, Serrano B, et al. Human papillomavirus and related diseases report. L'Hospitalet de Llobregat: ICO Information Centre on HPV and Cancer. Human Papillomavirus and Related Diseases in the World. Summary Report 17 June 2019.
[10]
Airede LR, Onakewhor JU, Aziken ME, Ande AB and, Aligbe JU. Carcinoma of the uterine cervix in Nigerian women: The need to adopt a national prevention strategy. Sahel Med J 2008; 11(1): 1-1.
[11]
Peirson L, Fitzpatrick-Lewis D, Ciliska D and, Warren R. Screening for cervical cancer: A systematic review and meta-analysis. Syst Rev 2013; 2(1): 35.
[12]
Wright KO, Aiyedehin O, Akinyinka MR, Ilozumba O. Cervical cancer: community perception and preventive practices in an urban neighborhood of Lagos (Nigeria). ISRN Prev Med 2014; 2014 950534
[13]
Bakari M, Takai IU and, Bukar M. Awareness and utilization of Papanicoloau smear among health care workers in Maiduguri, Nigeria. Niger J Basic Clin Sci 2015; 12(1): 34.
[14]
Okunowo AA, Daramola ES, Soibi-Harry AP, et al. Women’s knowledge of cervical cancer and uptake of Pap smear testing and the factors influencing it in a Nigerian tertiary hospital. J Cancer Res Pract 2018; 5(3): 105-11.
[15]
Center M, Siegel R, Jemal A. Global cancer facts & figures. JCRP 2011; 2011: 1-52.
[16]
Onah HE, Ezugwu FO, Eze JN. Cervical cancer screening: A survey of current practice amongst Nigerian gynaecologists. Trop J Obstet Gynaecol 2001; 18(2): 78-81.
[17]
Udigwe GO. Knowledge, attitude and practice of cervical cancer screening (pap smear) among female nurses in Nnewi, South Eastern Nigeria. Niger J Clin Pract 2006; 9(1): 40-3.
[18]
Owoeye IO, Ibrahim IA. Knowledge and attitude towards cervical cancer screening among female students and staff in a tertiary institution in the Niger Delta. IJMBR 2013; 2(1): 48-56.
[19]
Ajenifuja OK, Adepiti CA. Knowledge of cervical cancer and utilization of Pap smear among patients in a tertiary center in South West Nigeria. Ibom Med J 2008; 4: 45-62.
[20]
Bukar M, Audu BM. Women’s attitude towards cervical cancer screening in North Eastern Nigeria. Niger Med Pract 2011; 60(1-2): 13-8.
[21]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
[22]
Wright KO, Faseru B, Kuyinu YA, Faduyile FA. Awareness and uptake of the Pap smear among market women in Lagos, Nigeria. J Public Health Africa 2011; 2(1) e14
[23]
Al Sairafi M, Mohamed FA. Knowledge, attitudes, and practice related to cervical cancer screening among Kuwaiti women. Med Princ Pract 2009; 18(1): 35-42.
[24]
Muñoz N, Bosch FX, De Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-27.
[25]
Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer 2007; 7(1): 11.
[26]
Shirasawa H, Tomita Y, Kubota K, et al. Detection of human papillomavirus type 16 DNA and evidence for integration into the cell DNA in cervical dysplasia. J Gen Virol 1986; 67(9): 2011-5.
[27]
Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virol J 1987; 161(1): 259-61.
[28]
Shukla S, Mahata S, Shishodia G, et al. Physical state & copy number of high risk human papillomavirus type 16 DNA in progression of cervical cancer. Indian J Med Res 2014; 139(4): 531.
[29]
Ribeiro J, Teixeira D, Marinho-Dias J, et al. Characterization of human papillomavirus genotypes and HPV-16 physical status in cervical neoplasias of women from northern Portugal. Int J Gynaecol Obstet 2014; 125(2): 107-10.
[30]
Wei WF, Su GD, Wu LF, et al. Study of integrated state of HPV-16 infection in cervical cancer and precancerous tissues. Nan Fang Yi Ke Da Xue Xue Bao 2015; 35(1): 47-50.
[31]
Del Rio-Ospina L, Soto-De Leon SC, Camargo M, et al. Multiple high-risk HPV genotypes are grouped by type and are associated with viral load and risk factors. Epidemiol Infect 2017; 145(7): 1479-90.
[32]
Sohrabi A, Hajia M, Jamali F, Kharazi F. Is incidence of multiple HPV genotypes rising in genital infections? J Infect Public Health 2017; 10(6): 730-3.
[33]
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.
[34]
Manawapat A, Stubenrauch F, Russ R, Munk C, Kjaer SK, Iftner T. Physical state and viral load as predictive biomarkers for persistence and progression of HPV16-positive cervical lesions: Results from a population based long-term prospective cohort study. Am J Cancer Res 2012; 2(2): 192.
[35]
Freedman ML, Penney KL, Stram DO, et al. Common variation in BRCA2 and breast cancer risk: A haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 2004; 13(20): 2431-41.
[36]
Soung YH, Lee JW, Kim SY, et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res 2005; 65(3): 815-21.
[37]
Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene 2002; 21(57): 8843.
[38]
Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nature Genet 2007; 39(5): 605.
[39]
Yang JK. FLIP as an anti-cancer therapeutic target. Yonsei Med J 2008; 49(1): 19-27.
[40]
Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6(5): 1796-803.
[41]
Shi L, Baohua Z, Zehua W. Expression of survivin, cyclinD1, p21 WAF1, caspase-3 in cervical cancer and its relation with prognosis. J Huazhong Univ Sci Technol Med Sci 2005; 25(1): 78-81.
[42]
Espinosa M, Cantú D, Herrera N, et al. Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer 2006; 6(1): 45.
[43]
Oyervides-Muñoz MA, Pérez-Maya AA, Rodríguez-Gutiérrez HF, et al. Understanding the HPV integration and its progression to cervical cancer. Infect Genet Evol 2018; 61: 134-44.
[44]
Rusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus–associated cancers. Clin Cancer Res 2015; 21(9): 2009-19.
[45]
Boulet G, Horvath C, Broeck DV, Sahebali S and , Bogers J. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 2007; 39(11): 2006-11.
[46]
Hausen ZH. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2(5): 342.
[47]
Evans C, Dalgleish AG, Kumar D. Immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006; 24(8): 1163-77.
[48]
Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-75.
[49]
Tomao F, Papa A, Rossi L, et al. Angiogenesis and antiangiogenic agents in cervical cancer. OncoTargets Ther 2014; 7: 2237.
[50]
Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2(10): 795.
[51]
Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumour-induced immune suppression. Blood 2003; 101(12): 4878-86.
[52]
Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005; 174(1): 215-22.
[53]
Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1(10): 1024.
[54]
Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8(8): 579.
[55]
Chung SH, Franceschi S, Lambert PF. Estrogen and ERα: Culprits in cervical cancer? Trends Endocrinol Metab 2010; 21(8): 504-11.
[56]
Waggoner SE. Cervical cancer. Lancet 2003; 361(9376): 2217-25.
[57]
Chen CY, Liu TZ, Tseng WC, et al. Anonaine induces apoptosis through Bax-and caspase-dependent pathways in human cervical cancer (HeLa) cells. Food Chem Toxicol 2008; 46: 2694-702.
[58]
Chen SP, Dong M, Kita K, et al. Anti-proliferative and apoptosis-inducible activity of labdane and abietane diterpenoids from the pulp of Torreya nucifera in HeLa cells. Mol Med Rep 2010; 3: 673-8.
[59]
Takaya M, Nomura M, Takahashi T, Kondo Y, Lee KT, Kobayashi S. 23-Hydroxyursolic acid causes cell growth-inhibition by inducing caspase-dependent apoptosis in human cervical squamous carcinoma HeLa cells. Anticancer Res 2009; 29: 995-1000.
[60]
Won SJ, Ki YS, Chung KS, Choi JH, Bae KH, Lee KT. 3α, 23-isopropylidenedioxyolean-12-en-27-oic acid, a triterpene isolated from Aceriphyllum rossii, induces apoptosis in human cervical cancer HeLa cells through mitochondrial dysfunction and endoplasmic reticulum stress. Biol Pharm Bull 2010; 33: 1620-6.
[61]
Cao W, Li XQ, Wang X, et al. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway. Phytomedicine 2010; 17: 598-605.
[62]
Youn MJ, So HS, Cho HJ, et al. Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull 2008; 31: 789-95.
[63]
Singh M, Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009; 325: 107-19.
[64]
Yang Y, Yue Y, Runwei Y, Guolin Z. Cytotoxic, apoptotic and antioxidant activity of the essential oil of Amomum Tsao-ko. Bioresour Technol 2010; 101: 4205-11.
[65]
Chung KS, Choi JH, Back NI, et al. Eupafolin, a flavonoid isolated from Artemisia princeps, induced apoptosis in human cervical adenocarcinoma HeLa cells. Mol Nutr Food Res 2010; 54: 1318-28.
[66]
Liu RM, Zhong JJ. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine 2011; 18: 349-55.
[67]
Oh HL, Lim H, Park Y, et al. HY253, a novel compound isolated from Aralia continentalis, induces apoptosis via cytochrome c-mediated intrinsic pathway in HeLa cells. Bioorg Med Chem Lett 2009; 19: 797-9.
[68]
Xu W, Liu J, Li C, Wu HZ, Liu YW. Kaempferol-7-O-β-d-glucoside (KG) isolated from Smilax china L. rhizome induces G2/M phase arrest and apoptosis on HeLa cells in a p53-independent manner. Cancer Lett 2008; 264: 229-40.
[69]
Mandal SK, Biswas R, Bhattacharyya SS, et al. Lycopodine from Lycopodium clavatum extract inhibits proliferation of HeLa cells through induction of apoptosis via caspase-3 activation. Eur J Pharmacol 2010; 626: 115-22.
[70]
Liu Z, Liu B, Zhang ZT, et al. A mannose-binding lectin from Sophora flavescens induces apoptosis in HeLa cells. Phytomedicine 2008; 15: 867-75.
[71]
Shi YQ, Zhu CJ, Yuan HQ, et al. Marchantin C, a novel microtubule inhibitor from liverwort with anti-tumour activity both in vivo and in vitro. Cancer Lett 2009; 276: 160-70.
[72]
Lv H, Kong Y, Yao Q, et al. Nebrodeolysin, a novel hemolytic protein from mushroom Pleurotus nebrodensis with apoptosis-inducing and anti-HIV-1 effects. Phytomedicine 2009; 16: 198-205.
[73]
Feng C, Zhou LY, Yu T, et al. A new anticancer compound, oblongifolin C, inhibits tumour growth and promotes apoptosis in HeLa cells through Bax activation. Int J Cancer 2012; 131144554
[74]
Hu HZ, Yang YB, Xu XD, et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line 1. Acta Pharmacol Sin 2007; 28: 1819-26.
[75]
Ohtsuki T, Tamaki M, Toume K, Ishibashi M. A novel sesquiterpenoid dimer parviflorene F induces apoptosis by up-regulating the expression of TRAIL-R2 and a caspase-dependent mechanism. Bioorg Med Chem Lett 2008; 16: 1756-63.
[76]
Wang Q, Zheng XL, Yang L, et al. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res 2010; 29: 159.
[77]
Xiao JX, Huang GQ, Zhang SH. Soyasaponins inhibit the proliferation of HeLa cells by inducing apoptosis. Exp Toxicol Pathol 2007; 59: 35-42.
[78]
Zhou L, Chan WK, Xu N, et al. Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest. Life Sci J 2008; 83: 394-403.
[79]
Latifah SY, Ng WK, Al-Naqeeb G, Maznah I. Cytotoxicity of thymoquinone (TQ) from Nigella sativa towards human cervical carcinoma cell (HeLa). J Pharm Res 2009; 2: 585-9.
[80]
Wang P, Li JC. Trichosanthin-induced specific changes of cytoskeleton configuration were associated with the decreased expression level of actin and tubulin genes in apoptotic HeLa cells. Life Sci 2007; 81: 1130-40.
[81]
Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95(9): 1187-91.
[82]
Schellhas HF. Laser surgery in gynecology. In: The Biomedical Laser. Springer: New York, NY 1981; pp. 99-106.
[83]
Ayhan A, Boynukalin FK, Guven S, et al. Repeat LEEP conization in patients with cervical intraepithelial neoplasia grade 3 and positive ectocervical margins. Int J Gynaecol Obstet 2009; 105(1): 14-7.
[84]
Ramirez PT, Pareja R, Rendón GJ, Millan C, Frumovitz M, Schmeler KM. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol 2014; 132(1): 254-9.
[85]
Carter J, Sonoda Y, Abu-Rustum NR. Reproductive concerns of women treated with radical trachelectomy for cervical cancer. Gynecol Oncol 2007; 105(1): 13-6.
[86]
Kagabu T, Nanayama K. Pelvic lymph node dissection for cervical cancer. Nihon Naibunpi Gakkai Zasshi 1984; 36(12): 2657-60.
[87]
Gold MA, Tian C, Whitney CW, Rose PG, Lanciano R. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma. Cancer 2008; 112(9): 1954-63.
[88]
Petersen SS, Doe S, Buekers T. Definitive radiation therapy for cervical cancer: Non-white race and public insurance are risk factors for delayed completion, a pilot study. Gynecol Oncol Rep 2018; 25: 102-5.
[89]
Vulpe H, Asamoah FA, Maganti M, Vanderpuye V, Fyles A, Yarney J. External beam radiation therapy and brachytherapy for cervical cancer: The experience of the national centre for radiotherapy in Accra, Ghana. Int J Radiat Oncol Biol Phys 2018; 100(5): 1246-53.
[90]
Berger T, Assenholt MS, Seppenwoolde Y, et al. OC-0391: Evolution of external beam radiotherapy in cervix cancer: From EMBRACE I to EMBRACE II. Radiother Oncol 2018; 127: S200-1.
[91]
Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016; 120(3): 428-33.
[92]
Humphrey P, Bennett C, Cramp F. The experiences of women receiving brachytherapy for cervical cancer: A systematic literature review. Radiography 2018; 24(4): 396-403.
[93]
Robova H, Halaska MJ, Pluta M, et al. Oncological and pregnancy outcomes after high-dose density neoadjuvant chemotherapy and fertility-sparing surgery in cervical cancer. Gynecol Oncol 2014; 135(2): 213-6.
[94]
Board PA. Cervical cancer treatment (PDQ®). In: PDQ cancer information summaries. National Cancer Institute: US 2018.
[95]
Moon JY, Song IC, Ko YB, Lee HJ. The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer. Medicine 2018; 97(14)e0340
[96]
Hsu HC, Tsai SY, Wu SL, et al. Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Support Care Cancer 2017; 25(11): 3457-64.
[97]
Crafton SM, Salani R. Beyond chemotherapy: An overview and review of targeted therapy in cervical cancer. Clin Ther 2016; 38(3): 449-58.
[98]
Achampong Y, Kokka F, Doufekas K, Olaitan A. Prevention of Cervical Cancer. J Cancer Ther 2018; 9(01): 79.
[99]
Casak SJ, Lemery SJ, Chung J, et al. FDA’s approval of the first biosimilar to bevacizumab. Clin Cancer Res 2018; 24(18): 4365-70.
[100]
De Vincenzo R, Tortorella L, Ricci C, et al. Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome. Gynecol Oncol 2018; 150(3): 398-405.
[101]
Manci N, Marchetti C, Di Tucci C, et al. A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol 2011; 122(2): 285-90.
[102]
Saglam O, Conejo-Garcia J. PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 2018. [Epub ahead of print].
[103]
Klobocista M, Einstein MH, Runowicz CD. Cervical cancer. In: The American Cancer Society’s Oncology in Practice: Clinical Management. Wiley & Sons: New Jersey, USA 2018; p. 288.
[104]
Blowman K, Magalhães M, Lemos MFL, Cabral C, Pires IM. Anticancer properties of essential oils and other natural products. Evid Based Complement Alternat Med 2018; 20183149362
[105]
Silva SL, Chaar JD, Figueiredo PD, Yano T. Cytotoxic evaluation of essential oil from Casearia sylvestris Sw on human cancer cells and erythrocytes. Acta Amazon 2008; 38(1): 107-12.
[106]
Khalil AA. ur Rahman U, Khan MR, Sahar A, Mehmood T, Khan M. Essential oil eugenol: Sources, extraction techniques and nutraceutical perspectives. RSC Adv 2017; 7(52): 32669-81.
[107]
Angelini P, Tirillini B, Akhtar MS, et al. Essential Oil with Anticancer Activity: An Overview. In: Anticancer Plants: Natural Products and Biotechnological Implements. Springer: Singapore 2018; pp. 207-31.
[108]
Yan HC, Hong P, Yu ZZ, Jing S. Evaluation of antioxidant and antitumour activities of lemon essential oil. J Med Plants Res 2010; 4(18): 1910-5.
[109]
Mesa-Arango AC, Montiel-Ramos J, Zapata B, Durán C, Betancur-Galvis L, Stashenko E. Citral and carvone chemotypes from the essential oils of Colombian Lippia alba (Mill.) NE Brown: Composition, cytotoxicity and antifungal activity. Mem Inst Oswaldo Cruz 2009; 104(6): 878-84.
[110]
Singh N, Verma P, Pandey BR, Bhalla M. Therapeutic potential of Ocimum sanctum in prevention and treatment of cancer and exposure to radiation: An overview. Int J Pharm Sci Res 2012; 4(2): 97-104.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [49 - 61]
Pages: 13
DOI: 10.2174/1573394715666190126142508
Price: $65

Article Metrics

PDF: 17
HTML: 1